Abstract
Despite recent advances in the diagnoses and treatment of breast cancer, this disease continues to be a major cause of death. One of the biggest challenges in breast cancer treatment is bone metastasis. Breast cancer cells (BCCs) are capable of migrating to the bone marrow and utilizing the marrow microenvironment to remain quiescent. While exhibiting quiescence in the marrow, BCCs can evade the effects of conventional cancer treatments such as chemotherapy. Therefore, scientists must find a new paradigm to target these quiescent BCCs. The development of potential targets may require a more comprehensive understanding of the marrow microenvironment and its regulators. The preprotachykinin-1 (PPT-I) gene encodes for the tachykinin peptides, which interact with neurokinin (NK) receptors. Studies have correlated this interaction with BCC integration into the bone marrow and breast cancer progression. In this review, we discuss the roles that different factors of the marrow microenvironment play in breast cancer and targets of NK receptors as potential treatment options.
Keywords: Neurokinin receptor, breast cancer, tachykinins, CXCR4, SDF-1α, bone marrow, substance P, preprotachykinin-I
Current Drug Discovery Technologies
Title: Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Volume: 5 Issue: 1
Author(s): Pranela Rameshwar, Bobby Y. Reddy, Katarzyna A. Trzaska, Raghav G. Murthy and Peter Navarro
Affiliation:
Keywords: Neurokinin receptor, breast cancer, tachykinins, CXCR4, SDF-1α, bone marrow, substance P, preprotachykinin-I
Abstract: Despite recent advances in the diagnoses and treatment of breast cancer, this disease continues to be a major cause of death. One of the biggest challenges in breast cancer treatment is bone metastasis. Breast cancer cells (BCCs) are capable of migrating to the bone marrow and utilizing the marrow microenvironment to remain quiescent. While exhibiting quiescence in the marrow, BCCs can evade the effects of conventional cancer treatments such as chemotherapy. Therefore, scientists must find a new paradigm to target these quiescent BCCs. The development of potential targets may require a more comprehensive understanding of the marrow microenvironment and its regulators. The preprotachykinin-1 (PPT-I) gene encodes for the tachykinin peptides, which interact with neurokinin (NK) receptors. Studies have correlated this interaction with BCC integration into the bone marrow and breast cancer progression. In this review, we discuss the roles that different factors of the marrow microenvironment play in breast cancer and targets of NK receptors as potential treatment options.
Export Options
About this article
Cite this article as:
Rameshwar Pranela, Reddy Y. Bobby, Trzaska A. Katarzyna, Murthy G. Raghav and Navarro Peter, Neurokinin Receptors as Potential Targets in Breast Cancer Treatment, Current Drug Discovery Technologies 2008; 5 (1) . https://dx.doi.org/10.2174/157016308783769450
DOI https://dx.doi.org/10.2174/157016308783769450 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology C-Met Inhibitors are Potential Novel Therapeutic Agents Against Listeria monocytogenes Infection Through Blocking the Bacteria Entry into Nonphagocytic Cells
Current Topics in Medicinal Chemistry A Novel Small Molecule Inhibitor of FAK and IGF-1R Protein Interactions Decreases Growth of Human Esophageal Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research Promising Chemoprevention of Colonic Aberrant Crypt Foci by <i>Portunus segnis</i> Muscle and Shell Extracts in Azoxymethane-Induced Colorectal Cancer in Rats
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Synthesis and Anticancer Activity of Some Molecules Other Than Nitrogen Containing Heterocyclic Moeities
Mini-Reviews in Medicinal Chemistry Lymphocyte Homing to the Liver
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability
Current Drug Delivery The Medicinal Chemistry of Theragnostics, Multimodality Imaging and Applications of Nanotechnology in Cancer
Current Topics in Medicinal Chemistry Structure-Function Relationship of Vpr: Biological Implications
Current HIV Research Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets Linking Inflammation to Cell Cycle Progression
Current Pharmaceutical Design Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?
Current Molecular Medicine Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine Targeting the Viral Nucleocapsid Protein in Anti-HIV-1 Therapy
Mini-Reviews in Medicinal Chemistry